Investigational drug · Phase 2
Dactolisib
Also called: BEZ235, RTB101
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Respiratory Tract Infections, Covid19.
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 9, 2021 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
26
Any phase or sponsor naming "Dactolisib"
First trial start
2017
Nov 15, 2017
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Dactolisib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Respiratory Tract Infections
- Covid19
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "Dactolisib" as an intervention, largest first.
- A Phase 3 Study to Determine if RTB101 Prevents Clinically Symptomatic Respiratory Illness in the ElderlyPivotal-lookingCompleted
Restorbio Inc.Industry
NCT04668352 · 1,024 participants · Start Apr 15, 2019 · Primary completion Dec 2, 2019
Drug: Dactolisib · For: Respiratory Tract Infections
Sites: Wellington, New Zealand
- Dose Finding Study to Determine if BEZ235 Alone or in Combination With RAD001 Decreases the Incidence of Respiratory Tract Infections in the ElderlyPivotal-lookingActive, not recruiting
Restorbio Inc.Industry
NCT03373903 · 652 participants · Start Nov 15, 2017 · Primary completion May 3, 2018
Drug: BEZ235; BEZ235 plus everolimus (RAD001) · For: Respiratory Tract Infections
Sites: Wichita, Kansas
Novartis PharmaceuticalsNovartis (NVS)
NCT00620594 · 183 participants · Start Dec 21, 2006 · Primary completion Jan 8, 2013
Drug: BEZ235 · For: Breast Cancer; Advanced Solid Tumors; Cowden Syndrome
Sites: Los Angeles, California; New Haven, Connecticut; Boston, Massachusetts · 15 sites in all
- A Trial of Oral BEZ235 and BKM120 in Combination With Paclitaxel With or Without TrastuzumabCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01285466 · 110 participants · Start Jan 2011 · Primary completion Oct 2014
Drug: BEZ235 + paclitaxel; BKM120 + paclitaxel and 2 more · For: Metastatic or Locally Advanced Solid Tumors
Sites: Brussels, Belgium; Wilrijk, Belgium; Cologne, Germany · 10 sites in all
Vanderbilt-Ingram Cancer CenterAcademic, hospital or other
NCT01248494 · 72 participants · Start Nov 2010 · Primary completion Dec 2012
Drug: BEZ235; BKM 120 and 2 more · For: Metastatic Breast Cancer
Sites: Birmingham, Alabama; Boston, Massachusetts; New York, New York · 6 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT01628913 · 62 participants · Start Oct 2012 · Primary completion Sep 2014
Drug: BEZ235; Everolimus · For: Pancreatic Neuroendocrine Tumors (pNET)
Sites: Los Angeles, California; Aurora, Colorado; Lexington, Kentucky · 26 sites in all
- A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older AdultsActive, not recruiting
Restorbio Inc.Industry
NCT04584710 · 60 participants (planned) · Start Oct 13, 2020 · Primary completion Feb 2021
Drug: RTB101; Placebo · For: Covid19
Sites: Farmington, Connecticut; Roslindale, Massachusetts
Medical Research CouncilGovernment (non-federal)
NCT02430363 · 58 participants (planned) · Start Mar 2013 · Primary completion Jan 2016
Drug: MK - 3475; Suppressor of the PI3K/Akt pathways · For: Glioblastoma
Sites: Boston, Massachusetts; Houston, Texas; Brussels, Belgium · 13 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT01482156 · 46 participants · Start Jan 2012 · Primary completion Feb 2015
Drug: RAD001 + BEZ235 · For: Advanced Solid Tumors; Metastatic Breast Cancer; Metastatic Renal Cell Carcinoma
Sites: Fayetteville, Arkansas; St Louis, Missouri; Charleston, South Carolina · 10 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT01634061 · 43 participants · Start Sep 2012 · Primary completion Jul 2015
Drug: BEZ235; BKM120 and 2 more · For: Castration-resistant Prostate Cancer
Sites: Los Angeles, California; Hackensack, New Jersey; Brussels, Belgium · 10 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Identification of a DNA Damage Response-Related Prognostic Signature and Functional Validation of SMC3 in Glioma.
Ma J, Zhang C, Zhang J, et al. · Int J Mol Sci 2026
- Methylsulfonylmethane protects against lethal MRSA infection via binding to PIK3CB to increase macrophage phagocytic function and nitric oxide production.
Liu H, Tang W, Zheng H, et al. · Life Sci 2026
- Zang-Si-Wei and its core constituent ellagic acid alleviate LPS-induced acute lung injury by modulating PI3K/AKT signaling and NLRP3-associated pyroptosis.
Tang D, Song B, Wang H, et al. · Front Pharmacol 2026
- Dactolisib outperforms Rapamycin in potentiating apoptosis induced by XPO1, Bcl-2 and Mcl-1 blockade in preclinical glioblastoma models.
Zhao K, Meyer L, Braun M, et al. · FEBS Open Bio 2026
- Targeting PI3K/AKT/mTOR Pathway Exerts Inhibitory Effects on Endothelial Cells from Generalized Lymphatic Anomaly.
Lorusso B, Finato L, Nogara A, et al. · Cells 2026
- Combination of kale-derived exosomes and dactolisib promotes apoptosis and modulates iron homeostasis in Hep3B hepatocellular carcinoma cells.
Değirmenci NS, Zor Z, Pedük D, et al. · Mol Biol Rep 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.